Logo

Cambridge Epigenetix: Peter Fromen

Jun 14, 2022

Cambridge Epigenetix has appointed Peter Fromen as its CEO effective July 18. Current acting CEO Gail Marcus will continue as chair of the board. Fromen previously served as chief commercial officer of PacBio. Prior to that, he worked at Illumina, where he held leadership roles in investor relations, product marketing, market development, and enterprise sales. As Illumina's global vice president of population genomics and precision health, Fromen oversaw the firm's partnership with Genomics England and the National Health System to execute the 100,000 Genomes Project which led to the commissioning of whole genome sequencing in the NHS for rare diseases and certain cancers.

Breaking News
The Scan

Machine Learning Helps ID Molecular Mechanisms of Pancreatic Islet Beta Cell Subtypes in Type 2 Diabetes

The approach helps overcome limitations of previous studies that had investigated the molecular mechanisms of pancreatic islet beta cells, the authors write in their Nature Genetics paper.

Culture-Based Methods, Shotgun Sequencing Reveal Transmission of Bifidobacterium Strains From Mothers to Infants

In a Nature Communications study, culture-based approaches along with shotgun sequencing give a better picture of the microbial strains transmitted from mothers to infants.

Microbial Communities Can Help Trees Adapt to Changing Climates

Tree seedlings that were inoculated with microbes from dry, warm, or cold sites could better survive drought, heat, and cold stress, according to a study in Science.

A Combination of Genetics and Environment Causes Cleft Lip

In a study published in Nature Communications, researchers investigate what combination of genetic and environmental factors come into play to cause cleft lip/palate.